Giulia Scapin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giulia Scapin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bjørn Gunnar Voldborg
Technical University of Denmark
1 shared publication - Ece Cagdas
Department of Biotechnology and Biomedicine, Technical University of Denmark
1 shared publication - Hooman Hefzi
Department of Biotechnology and Biomedicine, Technical University of Denmark
1 shared publication - Judit Pina Agullet
Technical University of Denmark 1 Lyngby
1 shared publication Karoline Schousboe Fremming
National Biologics Facility, Technical University of Denmark
1 shared publication- Lars Keld Nielsen
Technical University of Denmark
1 shared publication
Latest Publications
- Open Access
The Role of Glycan Structures in Modulating GM-CSF Bioactivity: Insights from Glycoengineering
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein cytokine with therapeutic potential in cancer and neutropenia treatment. While glycosylation of GM-CSF reduces immunogenicity and enhances serum bioavailability, it can also diminish receptor binding and bioactivity. Based on transcriptomic analysis of human T lymphocytes reported previously, GM-CSF–producing cells exhibit elevated expression of Alpha-1,6-Mannosylglycoprotein 6-Beta-N-Acetylglucosaminyltransferase ( MGAT5 ), which encodes N-acetylglucosaminyltransferase V, an enzyme involved in N-glycan branching. Given this role of MGAT5 in glycosylation, we produced GM-CSF variants using glycoengineered Chinese hamster ovary cells to generate diverse glycoforms and assessed their bioactivity. Testing their activity on TF-1 cell proliferation, we found that decreases in GM-CSF N -glycan branching significantly suppressed its activity. These findings underscore the importance of glycosylation in modulating the efficacy and safety of GM-CSF-based therapeutics, suggesting that precise glycoengineering may be key to optimizing GM-CSF performance in clinical applications.
Open AccessThe Role of Glycan Structures in Modulating GM-CSF Bioactivity: Insights from Glycoengineering
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein cytokine with therapeutic potential in cancer and neutropenia treatment. While glycosylation of GM-CSF reduces immunogenicity and enhances serum bioavailability, it can also diminish receptor binding and bioactivity. Based on transcriptomic analysis of human T lymphocytes reported previously, GM-CSF–producing cells exhibit elevated expression of Alpha-1,6-Mannosylglycoprotein 6-Beta-N-Acetylglucosaminyltransferase ( MGAT5 ), which encodes N-acetylglucosaminyltransferase V, an enzyme involved in N-glycan branching. Given this role of MGAT5 in glycosylation, we produced GM-CSF variants using glycoengineered Chinese hamster ovary cells to generate diverse glycoforms and assessed their bioactivity. Testing their activity on TF-1 cell proliferation, we found that decreases in GM-CSF N -glycan branching significantly suppressed its activity. These findings underscore the importance of glycosylation in modulating the efficacy and safety of GM-CSF-based therapeutics, suggesting that precise glycoengineering may be key to optimizing GM-CSF performance in clinical applications.